長榮股份(300195.SZ):名軒投資7月3日通過大宗交易減持334.14萬股
格隆匯 7 月 6日丨長榮股份(300195.SZ)公佈,公司於2020年7月3日收到名軒投資的《關於減持天津長榮科技集團股份有限公司股票的告知函》,名軒投資於2020年7月3日通過深圳證券交易所大宗交易方式減持公司股份334.14萬股,佔公司扣除回購賬户股份後總股本比例0.79%。李莉及名軒投資在此次減持計劃期限內,將不再通過大宗交易方式減持。
截止公告日,控股股東、實際控制人李莉及其控制的名軒投資自2020年6月24日披露《簡式權益變動報告書》後,累計減持334.14萬股,佔公司扣除回購賬户股份後總股本比例0.79%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.